Tyrosine News and Research RSS Feed - Tyrosine News and Research

ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

The Alzheimer's Drug Discovery Foundation announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tasigna for use as a cancer therapy) in patients with Alzheimer's disease. [More]
Study helps identify optimal treatment option for NSCLC patients with brain metastases

Study helps identify optimal treatment option for NSCLC patients with brain metastases

A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer (NSCLC) with brain metastases to determine the best option for treatment. [More]
Association for Molecular Pathology announces winners of 2016 awards

Association for Molecular Pathology announces winners of 2016 awards

The Association for Molecular Pathology, the premier global, non-profit organization serving molecular diagnostics professionals, today announced the recipients of the Jeffrey A. Kant Leadership Award and the AMP Meritorious Service Award. Together with the AMP Award for Excellence in Molecular Diagnostics, these awards will be presented at the AMP 2016 Annual Meeting. [More]
Researchers discover new strategy to boost effectiveness of anti-cancer immune therapy

Researchers discover new strategy to boost effectiveness of anti-cancer immune therapy

Researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified a strategy to maximize the effectiveness of anti-cancer immune therapy. [More]
Study identifies new gene that suppresses breast cancer in mice

Study identifies new gene that suppresses breast cancer in mice

In recent years, the incidence of breast cancer has been increasing worldwide, and breast cancer is becoming a serious object of public concern. [More]
New drug holds potential for treating advanced mastocytosis

New drug holds potential for treating advanced mastocytosis

Most people have never heard of mastocytosis. It's a rare, sometimes deadly, immune disorder. Now new research may help those with advanced mastocytosis and possibly many more people, too. [More]
Study shows leptomeningeal metastases more prevalent in NSCLC patients with EGFR mutations

Study shows leptomeningeal metastases more prevalent in NSCLC patients with EGFR mutations

Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. [More]
Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Cancer remains a leading cause of death worldwide, and the global cancer burden is expected to increase by 70 percent over the next two decades. [More]
Phase III clinical study of promising prostate cancer drug reveals surprising results

Phase III clinical study of promising prostate cancer drug reveals surprising results

A recently published international clinical Phase III trial of a promising drug for treating advanced prostate cancer ended with surprising results: the new therapeutic agent failed to achieve any significant improvement in the overall survival of patients compared with the established standard treatment. [More]
Leukemia drug increases brain dopamine, lowers toxic proteins linked to Parkinson's or dementia

Leukemia drug increases brain dopamine, lowers toxic proteins linked to Parkinson's or dementia

A small phase I study provides molecular evidence that an FDA-approved drug for leukemia significantly increased brain dopamine and reduced toxic proteins linked to disease progression in patients with Parkinson's disease or dementia with Lewy bodies. [More]
Researchers discover new signaling events that trigger metastasis in ovarian cancer cells

Researchers discover new signaling events that trigger metastasis in ovarian cancer cells

Like pancreatic cancer, cancer of the ovaries is notorious for being discovered at a relatively late stage - after it has spread to other sites in the body. It is not called "the silent killer" for nothing. [More]
Researchers identify potential biomarkers predictive of TKIs response in metastatic renal cancer

Researchers identify potential biomarkers predictive of TKIs response in metastatic renal cancer

A team of CNIO researchers, in collaboration with the Spanish Oncology Genitourinary Group and the University Hospitals Leuven, has discovered various potential biomarkers predictive of tyrosine kinase inhibitors (TKIs) response in metastatic renal cancer. [More]
Nutritional interventions may help prevent detrimental brain ageing

Nutritional interventions may help prevent detrimental brain ageing

Ageing is a highly complex process marked by a succession of events that may lead to an altered brain function, including neurodegenerative diseases. To date, the precise cause of cognitive decline remains quite elusive. [More]
ALK fusion variants could influence NSCLC crizotinib response

ALK fusion variants could influence NSCLC crizotinib response

In non-small-cell lung cancer patients with anaplastic lymphoma kinase rearrangement treated with crizotinib, progression-free survival varies according to the ALK fusion variant. [More]
Why does appetite loss occur during illness? An interview with Prof. Conti and Prof. Francesconi

Why does appetite loss occur during illness? An interview with Prof. Conti and Prof. Francesconi

Appetite, as a word, come from the Latin appetitus, meaning "desire for.” Therefore, appetite can be defined as a pleasurable sensation or the desire to eat. This sensation is coordinated by several brain areas associated with reward processing such amygdala, hippocampus, ventral pallidum, nucleus accumbens and striatum, and others. [More]
Researchers investigate why N14Y, N14K mutations have distinct effects in KID syndrome patients

Researchers investigate why N14Y, N14K mutations have distinct effects in KID syndrome patients

A team of New York-based researchers has compared the effects of two disease-causing mutations, potentially explaining why patients with the rare genetic disorder keratitis-ichthyosis-deafness (KID) syndrome can experience different sets of symptoms. [More]
Potential therapeutic approaches to combat chronic myeloid leukemia

Potential therapeutic approaches to combat chronic myeloid leukemia

Chronic myeloid leukemia (CML) develops through chromosomal alterations in blood-forming cells of the bone marrow and usually occurs in older persons. Around 20 percent of adults diagnosed with leukemia suffer from this type of blood cancer. [More]
Breast cancer cells use new signaling pathway to cope with lack of oxygen levels inside tumors

Breast cancer cells use new signaling pathway to cope with lack of oxygen levels inside tumors

Researchers have identified a new signaling pathway that helps cancer cells cope with the lack of oxygen found inside tumors. These are the results of a study published in Nature Cell Biology on June 20, and led by researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center, Princess Margaret Cancer Center, the University of Toronto, Harvard Medical School and Oxford University. [More]
Cabozantinib extends advanced RCC overall survival

Cabozantinib extends advanced RCC overall survival

Patients with advanced or metastatic renal cell carcinoma derive a significant overall survival benefit from second-line treatment with the multi-tyrosine kinase inhibitor cabozantinib relative to everolimus. [More]
Salvage alloSCT remains option for progressing CML patients

Salvage alloSCT remains option for progressing CML patients

Research demonstrates the continuing role of allogeneic stem cell transplantation as a salvage option for patients with chronic myeloid leukaemia who progress to accelerated phase or blast crisis after tyrosine kinase inhibitor failure. [More]
Advertisement
Advertisement